Overview

Study of Quetiapine Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to-Severe Hypomanic Symptoms or Mild Manic Symptoms

Status:
Completed

Trial end date:
2007-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this research study is to evaluate the safety, tolerability, and efficacy of quetiapine compared to placebo (sugar pill without medication) in the treatment of bipolar disorder with moderate to severe hypomania or mild mania. Quetiapine is approved by the United States Food and Drug Administration (FDA) for the treatment of schizophrenia and bipolar mania.

Phase:

Phase 3

Details

Lead Sponsor:

Lindner Center of HOPE

Collaborators:

AstraZeneca
University of Cincinnati

Treatments:

Quetiapine Fumarate